GlassScriptPhysician profile
Julienne Cave
NPI 1396222436
$1,363.47
in general payments reported to CMS, 2019-2025
5 companies · $412 in 2025
The $412 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $375 · 2022: $122 · 2023: $30.28 · 2024: $425 · 2025: $412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $867.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $866.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $549.67 | 2021-2025 | Dysport |
| Merz North America, INC. | $287.05 | 2023-2025 | Xeomin |
| Revance Therapeutics, INC. | $279.88 | 2025 | Daxxify |
| Amgen INC. | $125.00 | 2021 | |
| Blueprint Medicines Corporation | $121.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julienne Cave listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.